Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | D527G |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 D527G lies within WD repeat 4 of the Fbxw7 protein (UniProt.org). D527G retains the ability to target Myc, Mcl-1, Braf, and Cyclin E for degradation (PMID: 32907612 , PMID: 27247421), binds to the large T antigen of Merkel cell polyomavirus similar to wild-type Fbxw7, and demonstrates increased binding to small T antigen in culture (PMID: 32427880), but results in decreased binding to Mlst8 (PMID: 34741373), fails to bind and degrade NICD in cultured cells leading to increased Notch transcriptional activity in a reporter assay, and results in transformation in the context of the viral protein, Tax, in culture (PMID: 27247421), and therefore, is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 D527G |
Transcript | NM_033632.3 |
gDNA | chr4:g.152326070T>C |
cDNA | c.1580A>G |
Protein | p.D527G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001349798.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
NM_018315.5 | chr4:g.152324219T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152326070T>C | c.1580A>G | p.D527G | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|